Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data from the CANVAS Program.
Conclusions : The effect of canagliflozin on cardiovascular and renal outcomes was not modified by baseline level of kidney function in people with type 2 diabetes and a history or high risk of cardiovascular disease down to eGFR levels of 30 mL/min/1.73 m2 Reassessing current limitations on the use of canagliflozin in CKD may allow additional individuals to benefit from this therapy. Clinical Trial Registration : URL: https://clinicaltrials.gov. Unique identifiers: NCT01032629, NCT01989754.
PMID: 29941478 [PubMed - as supplied by publisher]
Source: Circulation - Category: Cardiology Authors: Neuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW, Fulcher G, Desai M, Li Q, Deng H, Rosenthal N, Jardine MJ, Bakris G, Perkovic V Tags: Circulation Source Type: research
More News: Canagliflozin | Cardiology | Cardiovascular | Chronic Kidney Disease | Clinical Trials | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Heart Attack | Invokana | Stroke | Study | Urology & Nephrology